Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
MedImmune LLC |
---|---|
Information provided by: | MedImmune LLC |
ClinicalTrials.gov Identifier: | NCT00111878 |
The primary objective of this study is to describe the safety and tolerability of a single dose of MEDI-534 when administered to healthy adult volunteers.
Condition | Intervention | Phase |
---|---|---|
Respiratory Syncytial Virus Infections Parainfluenza Infections |
Drug: MEDI-534 |
Phase I |
Study Type: | Observational |
Study Design: | Natural History, Longitudinal, Defined Population, Prospective Study |
Official Title: | Dose-Escalating Study to Evaluate MEDI-534 in Healthy Adults |
Ages Eligible for Study: | 18 Years to 40 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Ohio | |
Children's Hospital | |
Columbus, Ohio, United States, 43205 | |
United States, Pennsylvania | |
Primary Physicians Research | |
Pittsburgh, Pennsylvania, United States, 15241 | |
United States, Texas | |
Radiant Research | |
Dallas, Texas, United States, 75247 |
Study Director: | Margarita Gomez, MD | MedImmune LLC |
Study ID Numbers: | MI-CP119 |
Study First Received: | May 26, 2005 |
Last Updated: | July 2, 2007 |
ClinicalTrials.gov Identifier: | NCT00111878 |
Health Authority: | United States: Food and Drug Administration |
Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) |
Virus Diseases Paramyxoviridae Infections Parainfluenza virus type 3 Healthy Respiratory Syncytial Virus Infections |
Communicable Diseases Pneumovirus Infections RNA Virus Infections Infection Mononegavirales Infections |